
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna is a biotech company that has a strong outlook due to its successful mRNA technology, which was validated by its rapid development of a COVID-19 vaccine. With a wide range of clinical studies in various therapeutic areas, including oncology and cardiovascular disease, and a strong focus on personalized medicine, the company is poised for future growth. Moderna also has a solid financial position, with projected product sales of $1.73 billion in 2025 that could potentially reach $3.5 billion by 2028. Additionally, the company has a diverse workforce, with 50% female employees and a good representation of different racial and ethnic backgrounds.
Bears say
Moderna is a relatively young company, with only a decade of operations and an IPO less than three years ago. While the COVID vaccine was a major success, there are significant risks associated with clinical trials and regulatory approval for their 35 mRNA development candidates. Their growth plans are optimistic and heavily dependent on future product sales, and the recent failure of the CMV vaccine has resulted in a significant reduction in their overall value. This, coupled with relatively early-stage programs in rare diseases, make Moderna's stock a high-risk investment.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares